CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Fundamental Health Sciences from the University of São Paulo (2010) and PhD in Biotechnology from the University of São Paulo (2015). Postdoctoral fellow at Massachusetts Institute of Technology - MIT. She is currently adjunct professor at the Department of Clinical and Experimental Oncology of the Federal University of São Paulo (UNIFESP) and advisor registered in the Program of Hematology and Oncology of UNIFESP. Has experience in Cancer, focusing on Molecular Biology, acting on the following subjects: Resistance to chemotherapy, DNA repair and use of CRISPR / Cas9 gene editing system (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Cancer is a leading cause of death worldwide, and while great advances have been made particularly in chemotherapy, many types of cancer still present a dismal prognosis. Glioma is the most common primary cancer of the central nervous system, and around half of the patients present with the most aggressive form of the disease, glioblastoma. The alkylating agent temozolomide (TMZ) is the f…
Cancer is a leading cause of death worldwide, and while great advances have been made particularly in chemotherapy, many types of cancer still present a dismal prognosis. Glioma is the most common primary cancer of the central nervous system, and around half of the patients present with the most aggressive form of the disease, glioblastoma. Metastatic melanoma shares several of glioma's f…
Cancer is a leading cause of death worldwide, and while great advances have been made particularly in chemotherapy, many types of cancer still present a dismal prognosis. Glioma is the most common primary cancer of the central nervous system, and around half of the patients present with the most aggressive form of the disease, glioblastoma. Metastatic melanoma shares several of glioma's f…
NRF2 is a transcription factor that plays a central role in the cellular response to oxidative stress. Mutations in the KEAP1/NRF2 pathway are relatively common in lung cancer and are often associated with poor patient prognosis. This is due to resistance to major treatments, such as chemotherapy and immunotherapy, since antioxidant genes are induced, protecting tumor cells against cell d…
Glioblastoma represents a devastating diagnosis for the patient, considering that, without treatment, its average survival is only 4 months. This time is increased to 12 months after physiological resection followed by radiotherapy, with the combination of temozolomide (TMZ), standard chemotherapy, adding only another 3 months to this period. Precisely the frequent development of resistan…
Cancer is highlighted as one of the main causes of death today, and its treatment is a worldwide concern. Therapeutic interventions have been based on radiotherapy and chemotherapy, the latter very focused on activating cell death pathways in tumorigenic cells. Despite this, chemotherapy-resistant tumors have been shown to be a complicating factor, making the treatment process difficult a…
Approximately 20-30% of non-small cell lung cancers (NSCLC) have mutations in the NRF2 pathway. Due to their ability to induce the expression of antioxidant genes and protect the tumor cell from cell death, these mutations have been associated with a poor prognosis and resistance to chemotherapy and immunotherapies. Ferroptosis is a recently discovered type of programmed cell death, which…
Glioblastoma is an extremely aggressive type of cancer and patients with this type of tumor have a median survival between 12 and 15 months. Almost all patients succumb to the disease due to chemotherapy resistance. Standard chemotherapy treatment is performed through the administration of temozolomide (TMZ) which is an alkylating agent that induces cell death through the formation of var…
Chemotherapy resistance is the cause of failure in most patients with metastatic cancer. NRF2 is an important gene involved in chemotherapy resistance through its ability to regulate genes related to the antioxidant response, as well as prevent the cell from cell death processes, such as ferroptosis. Ferroptosis has been increasingly studied as an alternative in antitumor therapy. Ferropt…
(Only some records are available in English at this moment)
Lung cancer is one of most prevalent and aggressive type of tumor, characterized by the highly molecular heterogenicity. Mutations in the KEAP1/NRF2 pathway occur in approximately 20-30% of non-small cell lung cancers (NSCLC). These mutations are associated with poor prognosis and resistance to chemotherapy and immunotherapy due to their ability to induce antioxidant genes expression and,…
Cancer is one of the major causes of death today, and its treatment is a worldwide concern. Although many advances have been made in this area, the emergence of resistance is quite frequent favoring the disease's fatality. This process is closely associated with cell regulation systems, which are central in terms of therapeutic targets. In this sense, NRF2 is a transcription factor, invol…
Cancer is a leading cause of death worldwide. Although great advances have been made in cancer treatment, chemotherapy resistance remains a great clinical challenge and, as a consequence, it is one of the main causes of failure in most patients with metastatic cancer. NRF2 is an important gene involved in drug resistance and has been identified as amplified in the most aggressive types of…
Different types of cancer figure among the leading causes of morbidity, and mortality worldwide. The main factor for cancer treatment failure is antitumoral therapy resistance. Several mechanisms command drug resistance and many of those can be tissue or drug-specific (or both). As different pathways might contribute to tumor chemoresistance in different proportions, it is fundamental to …
| 1 / 1 | Ongoing grants |
| 2 / 2 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 10 / 9 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 3 / 3 | Completed scholarships abroad |
| 20 / 19 | All research grants and scholarships |
| Associated processes | |